LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

Kodu・Aktsiate loetelu・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Avatud

SektorTervishoid

9.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.48

Max

9.77

Põhinäitajad
By Trading Economics
Sissetulek	-1.1B -722M
Müük	-250M 156M
P/E Sektori keskmine	7.603 51.415
Aktsiakasum	0.141
Kasumimarginaal	-461.478
Töötajad	435
EBITDA	-968M -702M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+154.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-157M 2.2B
Eelmine avamishind	9.57
Eelmine sulgemishind	9.57

Uudiste sentiment

By Acuity

20%

80%

45 / 346 Pingereas Healthcare

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2026, 22:54 UTC

Tulu

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. mai 2026, 23:17 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. mai 2026, 23:16 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. mai 2026, 23:15 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. mai 2026, 23:14 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. mai 2026, 23:02 UTC

Market Talk

Tulu

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. mai 2026, 22:59 UTC

Market Talk

Tulu

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. mai 2026, 22:24 UTC

Tulu

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Revenue Growth 47%>XRO.AU

13. mai 2026, 22:22 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. mai 2026, 22:18 UTC

Tulu

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. mai 2026, 22:16 UTC

Tulu

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. mai 2026, 22:13 UTC

Tulu

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. mai 2026, 22:12 UTC

Tulu

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero Did Not Declare a Dividend>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. mai 2026, 22:09 UTC

Tulu

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. mai 2026, 22:00 UTC

Tulu

Cisco to Shed Jobs for All-In AI Push -- Update

13. mai 2026, 21:11 UTC

Tulu

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

154.89% tõus

12 kuu keskmine prognoos

Keskmine 22.43 USD 154.89%

Kõrge 32 USD

Madal 13 USD

Põhineb 8 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi BioCryst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

45 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.